A 12-year-old boy is battling a severe illness. He has become a focal point in a growing controversy. The controversy surrounds the ethics of financial speculation on medical research. The child has a very aggressive tumor. The tumor is located inches below his heart. He is undergoing treatment through a clinical trial. His father, Joshua Pederson, is a professor at Boston University. He is also the author of 'Sin Sick: Moral Injury in War and Literature.' Pederson has become a vocal critic of Kalshi. Kalshi is the prediction market that plans to enable people to wager on the outcomes of clinical trials. People may also wager on FDA regulatory decisions. After the cancer returned in his son two years after an initial diagnosis, Pederson enrolled his son in a new trial. The trial features a novel combination of chemotherapy and immunotherapy.
The treatment, though offering some hope, has produced only mixed early results. The family continues the grueling cycles of therapy. The initial offerings included contracts related to an anti-cancer drug's approval and the success of an Alzheimer’s treatment trial. These developments have raised ethical concerns, as patients with these diseases are hoping for breakthroughs while potential financial speculators may profit from failures.
The CEO's justification
The CEO of Kalshi, Tarek Mansour, has defended the initiative. He claims the market aims to 'surface information' through a 'continuously updated, public probability that reflects the weight of the evidence.' He argues that the pharmaceutical industry is 'one of the most important and information-constrained industries on earth.' He also says crucial data affecting drug development is 'largely locked away from the people who need it most.' According to Mansour, the system is designed to create transparency. It does this by aggregating public knowledge into real-time probabilities.
Despite this explanation, critics argue the outcome is still troubling. Individuals can profit by predicting whether a drug will be approved. They can also profit by predicting whether a trial will succeed. The CEO insists the market is not designed to 'bet against' life-saving treatments. This framing does not eliminate a perception. The perception is that people are financially interested in treatment failures.
Ethical concerns rise
For Pederson, the idea that someone could be wagering on the outcome of his son's clinical trial is 'enraging.' He questions how this is not another form of 'death market.' This would be akin to those for war or assassination. Kalshi explicitly says it will not offer such markets. Though Kalshi is currently not permitting bets on treatments for children, Mansour has repeatedly described a vision. He described a vision in which 'any difference in opinion' is wagerable. This suggests the company envisions a future. In that future, even children's medical trials could be subjects of financial speculation.
The situation becomes more precarious when combined with regulatory inaction. The Trump administration has taken steps to prevent the sector from being heavily regulated, which has allowed markets like Kalshi to operate with minimal oversight. Pederson worries that the trial his son is in could soon become another 'difference in opinion' open to betting. Even as the prediction market moves forward with its pilot, many ethical concerns remain unaddressed.
The treatment his son is undergoing has serious side effects, some immediate and others that may manifest years later. Given the high failure rate of clinical trials, Pederson finds the idea of relying on a prediction market to guide medical decisions 'preposterous.' Experts have also warned that such betting could interfere with the progress of life-saving research. Despite these concerns, Kalshi continues its expansion. Pederson remains deeply troubled by what the market might bring to the table. 'Maybe that won’t happen,' he says. 'But I wouldn’t bet on it.'